FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281640295> ?p ?o ?g. }

• W4281640295 endingPage "3584" @default.
• W4281640295 startingPage "3584" @default.
• W4281640295 abstract "3584 Background: Trifluridine/tipiracil (TAS-102) is currently approved as third-line treatment in metastatic colorectal cancer (mCRC). However, there is paucity of real-world data on the tolerability and efficacy with biweekly dosing as monotherapy or in combination with bevacizumab. In this study, we present our center’s experience with biweekly TAS-102 with or without bevacizumab in mCRC patients (pts). Methods: We performed a single center retrospective observational study of pts receiving TAS-102 between 2018 and 2021. Results: A total of 83 pts were included (53 men, 30 women), with a median age of 64 years. Majority of pts were treated with TAS-102 in the 3rd-line (48.2%) and 4th-line (28.9%) setting. Almost all (94.0%) were of ECOG ≤ 1 at the initiation of treatment. The mean number of cycles administered was 3.8 and bevacizumab (5mg/kg on Day 1, every 2 weeks) was used in combination with TAS-102 in 18 pts (21.7%). Majority of pts (84.3%) were given TAS-102 using the biweekly regimen (35mg/m2 BD, on Day 1-5 and 15-19, q28 days) rather than standard regimen (35mg/m2 BD, on Day 1-5 and 8-12, q28 days) following a change in institutional practice. Fifteen pts (18.1%) had their initial dose reduced to 30mg/m2 BD at prescriber's discretion. Median PFS and OS were 2.37 and 10.15 months, respectively. In terms of tolerability, fatigue (any grade, 42.2%) and neutropenia (any grade, 44.6%) were the two most common adverse events reported. Grade 3 or higher neutropenia and febrile neutropenia were 16.9% and 3.6%, respectively. Dose reduction during treatment was required in 15 pts (18.1%), dose delay in 31 pts (37.3%) and six pts (7.2%) discontinued treatment due to toxicity. More than half (54.2%) had at least an additional line of therapy (regorafenib, clinical trials or re-challenge previous chemotherapy agents) following disease progression with TAS-102. Conclusions: We report the largest real-world experience with biweekly TAS-102. Our pts treated with TAS-102 had comparable median PFS to the RECOURSE cohort but with significantly better OS as more than half continued to receive treatment. Biweekly dosing of TAS-102 with or without bevacizumab is well tolerated with significantly lower rates of Grade 3 neutropenia compared to the published data in the literature." @default.
• W4281640295 created "2022-06-13" @default.
• W4281640295 creator A5001797764 @default.
• W4281640295 creator A5011795536 @default.
• W4281640295 creator A5019135614 @default.
• W4281640295 creator A5039464515 @default.
• W4281640295 creator A5042086613 @default.
• W4281640295 creator A5045076272 @default.
• W4281640295 creator A5046625124 @default.
• W4281640295 creator A5053619368 @default.
• W4281640295 creator A5062844469 @default.
• W4281640295 creator A5081767464 @default.
• W4281640295 creator A5081851768 @default.
• W4281640295 creator A5085980773 @default.
• W4281640295 creator A5091531407 @default.
• W4281640295 date "2022-06-01" @default.
• W4281640295 modified "2023-10-18" @default.
• W4281640295 title "Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer." @default.
• W4281640295 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3584" @default.
• W4281640295 hasPublicationYear "2022" @default.
• W4281640295 type Work @default.
• W4281640295 citedByCount "1" @default.
• W4281640295 countsByYear W42816402952023 @default.
• W4281640295 crossrefType "journal-article" @default.
• W4281640295 hasAuthorship W4281640295A5001797764 @default.
• W4281640295 hasAuthorship W4281640295A5011795536 @default.
• W4281640295 hasAuthorship W4281640295A5019135614 @default.
• W4281640295 hasAuthorship W4281640295A5039464515 @default.
• W4281640295 hasAuthorship W4281640295A5042086613 @default.
• W4281640295 hasAuthorship W4281640295A5045076272 @default.
• W4281640295 hasAuthorship W4281640295A5046625124 @default.
• W4281640295 hasAuthorship W4281640295A5053619368 @default.
• W4281640295 hasAuthorship W4281640295A5062844469 @default.
• W4281640295 hasAuthorship W4281640295A5081767464 @default.
• W4281640295 hasAuthorship W4281640295A5081851768 @default.
• W4281640295 hasAuthorship W4281640295A5085980773 @default.
• W4281640295 hasAuthorship W4281640295A5091531407 @default.
• W4281640295 hasConcept C121608353 @default.
• W4281640295 hasConcept C126322002 @default.
• W4281640295 hasConcept C141071460 @default.
• W4281640295 hasConcept C143998085 @default.
• W4281640295 hasConcept C197934379 @default.
• W4281640295 hasConcept C2776694085 @default.
• W4281640295 hasConcept C2777063308 @default.
• W4281640295 hasConcept C2777802072 @default.
• W4281640295 hasConcept C2778375690 @default.
• W4281640295 hasConcept C2781413609 @default.
• W4281640295 hasConcept C526805850 @default.
• W4281640295 hasConcept C71924100 @default.
• W4281640295 hasConceptScore W4281640295C121608353 @default.
• W4281640295 hasConceptScore W4281640295C126322002 @default.
• W4281640295 hasConceptScore W4281640295C141071460 @default.
• W4281640295 hasConceptScore W4281640295C143998085 @default.
• W4281640295 hasConceptScore W4281640295C197934379 @default.
• W4281640295 hasConceptScore W4281640295C2776694085 @default.
• W4281640295 hasConceptScore W4281640295C2777063308 @default.
• W4281640295 hasConceptScore W4281640295C2777802072 @default.
• W4281640295 hasConceptScore W4281640295C2778375690 @default.
• W4281640295 hasConceptScore W4281640295C2781413609 @default.
• W4281640295 hasConceptScore W4281640295C526805850 @default.
• W4281640295 hasConceptScore W4281640295C71924100 @default.
• W4281640295 hasIssue "16_suppl" @default.
• W4281640295 hasLocation W42816402951 @default.
• W4281640295 hasOpenAccess W4281640295 @default.
• W4281640295 hasPrimaryLocation W42816402951 @default.
• W4281640295 hasRelatedWork W1964567729 @default.
• W4281640295 hasRelatedWork W2051540233 @default.
• W4281640295 hasRelatedWork W2087736549 @default.
• W4281640295 hasRelatedWork W2101986864 @default.
• W4281640295 hasRelatedWork W2122166711 @default.
• W4281640295 hasRelatedWork W2325657449 @default.
• W4281640295 hasRelatedWork W2546154929 @default.
• W4281640295 hasRelatedWork W3145383579 @default.
• W4281640295 hasRelatedWork W3203896279 @default.
• W4281640295 hasRelatedWork W4281640295 @default.
• W4281640295 hasVolume "40" @default.
• W4281640295 isParatext "false" @default.
• W4281640295 isRetracted "false" @default.
• W4281640295 workType "article" @default.